<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15328120</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0066-4804</ISSN><JournalIssue CitedMedium="Print"><Volume>48</Volume><Issue>9</Issue><PubDate><Year>2004</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone.</ArticleTitle><Pagination><StartPage>3523</StartPage><EndPage>3529</EndPage><MedlinePgn>3523-9</MedlinePgn></Pagination><Abstract><AbstractText>Enterovirus 71 is one of the most important pathogens in the family of Picornaviridae that can cause severe complications in the postpoliovirus era, such as encephalitis, pulmonary edema, and even death. Pyridyl imidazolidinone is a novel class of potent and selective human enterovirus 71 inhibitor. Pyridyl imidazolidinone was identified by using computer-assisted drug design. This virologic investigation demonstrates that BPR0Z-194, one of the pyridyl imidazolidinones, targets enterovirus 71 capsid protein VP1. Time course experiments revealed that BPR0Z-194 effectively inhibited virus replication in the early stages, implying that the compound can inhibit viral adsorption and/or viral RNA uncoating. BPR0Z-194 was used to select and characterize the drug-resistant viruses. Sequence analysis of the VP1 region showed that the resistant variants differed consistently by seven amino acids in VP1 region from their parental drug-sensitive strains. Site-directed mutagenesis of enterovirus 71 infectious cDNA revealed that a single amino acid alteration at the position 192 of VP1 can confer resistance to the inhibitory effects of BPR0Z-194.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>Shin-Ru</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>School of Medical Technology, Chang Gung University, 259 Wen-Hua First Rd., Kwei-Shan, Tao-Yuan, Taiwan. srshih@mail.cgu.edu.tw</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Mun-Chung</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Sung-Nien</ForeName><Initials>SN</Initials></Author><Author ValidYN="Y"><LastName>Won</LastName><ForeName>Kuo-Fang</ForeName><Initials>KF</Initials></Author><Author ValidYN="Y"><LastName>Shia</LastName><ForeName>Kak-Shan</ForeName><Initials>KS</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wen-Tai</ForeName><Initials>WT</Initials></Author><Author ValidYN="Y"><LastName>Chern</LastName><ForeName>Jyh-Haur</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Guang-Wu</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chung-Chi</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yen-Chun</ForeName><Initials>YC</Initials></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Kuan-Chang</ForeName><Initials>KC</Initials></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Yu-Sheng</ForeName><Initials>YS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D036022">Capsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018076">DNA, Complementary</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>KOR0084D0O</RegistryNumber><NameOfSubstance UI="C492441">1-(5-(4-bromophenoxy)pentyl)-3-(4-pyridyl)-2-imidazolidinone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036022" MajorTopicYN="N">Capsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018076" MajorTopicYN="N">DNA, Complementary</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="N">Enterovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016296" MajorTopicYN="N">Mutagenesis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010948" MajorTopicYN="N">Viral Plaque Assay</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>8</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>8</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2004</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15328120</ArticleId><ArticleId IdType="pmc">PMC514779</ArticleId><ArticleId IdType="doi">10.1128/AAC.48.9.3523-3529.2004</ArticleId><ArticleId IdType="pii">48/9/3523</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>AbuBakar, S., Y. F. Chan, and S. K. Lam. 2000. Outbreaks of enterovirus 71 infection. N. Engl. J. Med. 342:355-356.</Citation><ArticleIdList><ArticleId IdType="pubmed">10660400</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander, J. P., Jr., L. Baden, M. A. Pallansch, and L. J. Anderson. 1994. Enterovirus 71 infections and neurologic disease&#x2014;United States, 1977-1991. J. Infect. Dis. 169:905-908.</Citation><ArticleIdList><ArticleId IdType="pubmed">8133108</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergelson, J. M., M. P. Shepley, B. M. Chan, M. E. Hemler, and R. W. Finberg. 1992. Identification of the integrin VLA-2 as a receptor for echovirus 1. Science 255:1718-1720.</Citation><ArticleIdList><ArticleId IdType="pubmed">1553561</ArticleId></ArticleIdList></Reference><Reference><Citation>Billich, A. 2000. Pleconaril Sanofi Synthelabo/ViroPharma. Curr. Opin. Investig. Drugs 1:303-307.</Citation><ArticleIdList><ArticleId IdType="pubmed">11249712</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, L. Y., Y. C. Huang, and T. Y. Lin. 1998. Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease. Lancet 352:367-368.</Citation><ArticleIdList><ArticleId IdType="pubmed">9717926</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumakov, M., M. Voroshilova, L. Shindarov, I. Lavrova, L. Gracheva, G. Koroleva, S. Vasilenko, I. Brodvarova, M. Nikolova, S. Gyurova, M. Gacheva, G. Mitov, N. Ninov, E. Tsylka, I. Robinson, M. Frolova, V. Bashkirtsev, L. Martiyanova, and V. Rodin. 1979. Enterovirus 71 isolated from cases of epidemic poliomyelitis-like disease in Bulgaria. Arch. Virol. 60:329-340.</Citation><ArticleIdList><ArticleId IdType="pubmed">228639</ArticleId></ArticleIdList></Reference><Reference><Citation>Diana, G. D., M. A. McKinlay, M. J. Otto, V. Akullian, and C. Oglesby. 1985. [[(4,5-Dihydro-2-oxazolyl)phenoxy]alkyl]isoxazoles: inhibitors of picornavirus uncoating. J. Med. Chem. 28:1906-1910.</Citation><ArticleIdList><ArticleId IdType="pubmed">2999407</ArticleId></ArticleIdList></Reference><Reference><Citation>Dove, A. W., and V. R. Racaniello. 2000. An antiviral compound that blocks structural transitions of poliovirus prevents receptor binding at low temperatures. J. Virol. 74:3929-3931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC111905</ArticleId><ArticleId IdType="pubmed">10729171</ArticleId></ArticleIdList></Reference><Reference><Citation>Greve, J. M., G. Davis, A. M. Meyer, C. P. Forte, S. C. Yost, C. W. Marlor, M. E. Kamarck, and A. McClelland. 1989. The major human rhinovirus receptor is ICAM-1. Cell 56:839-847.</Citation><ArticleIdList><ArticleId IdType="pubmed">2538243</ArticleId></ArticleIdList></Reference><Reference><Citation>Groarke, J. M., and D. C. Pevear. 1999. Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants. J. Infect. Dis. 179:1538-1541.</Citation><ArticleIdList><ArticleId IdType="pubmed">10228078</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadfield, A. T., M. A. Oliveira, K. H. Kim, I. Minor, M. J. Kremer, B. A. Heinz, D. Shepard, D. C. Pevear, R. R. Rueckert, and M. G. Rossmann. 1995. Structural studies on human rhinovirus 14 drug-resistant compensation mutants. J. Mol. Biol. 253:61-73.</Citation><ArticleIdList><ArticleId IdType="pubmed">7473717</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz, B. A., R. R. Rueckert, D. A. Shepard, F. J. Dutko, M. A. McKinlay, M. Fancher, M. G. Rossmann, J. Badger, and T. J. Smith. 1989. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J. Virol. 63:2476-2485.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC250706</ArticleId><ArticleId IdType="pubmed">2542566</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho, M. 2000. Enterovirus 71: the virus, its infections and outbreaks. J. Microbiol. Immunol. Infect. 33:205-216.</Citation><ArticleIdList><ArticleId IdType="pubmed">11269363</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho, M., E. R. Chen, K. H. Hsu, S. J. Twu, K. T. Chen, S. F. Tsai, J. R. Wang, S. R. Shih, et al. 1999. An epidemic of enterovirus 71 infection in Taiwan. N. Engl. J. Med. 341:929-935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogle, J. M., M. Chow, and D. J. Filman. 1985. Three-dimensional structure of poliovirus at 2.9 &#xc5; resolution. Science 229:1358-1365.</Citation><ArticleIdList><ArticleId IdType="pubmed">2994218</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandolf, R. 1995. The molecular pathogenesis of enterovirus myocarditis. Virus persistence and chronic inflammation. Internist 36:430-438. (In German.)</Citation><ArticleIdList><ArticleId IdType="pubmed">7601616</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinlay, M. A. 1985. WIN 51711, a new systematically active broad-spectrum antipicornavirus agent. J. Antimicrob. Chemother. 16:284-286.</Citation><ArticleIdList><ArticleId IdType="pubmed">4055541</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendelsohn, C. L., E. Wimmer, and V. R. Racaniello. 1989. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56:855-865.</Citation><ArticleIdList><ArticleId IdType="pubmed">2538245</ArticleId></ArticleIdList></Reference><Reference><Citation>Modlin, J. F., R. Dagan, L. E. Berlin, D. M. Virshup, R. H. Yolken, and M. Menegus. 1991. Focal encephalitis with enterovirus infections. Pediatrics 88:841-845.</Citation><ArticleIdList><ArticleId IdType="pubmed">1896296</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore, D. M., and K. M. Cowan. 1978. Effect of trypsin and chymotrypsin on the polypeptides of large and small plaque variants of foot-and-mouth disease virus: relationship to specific antigenicity and infectivity. J. Gen. Virol. 41:549-562.</Citation><ArticleIdList><ArticleId IdType="pubmed">84854</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosser, A. G., J. Y. Sgro, and R. R. Rueckert. 1994. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J. Virol. 68:8193-8201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC237285</ArticleId><ArticleId IdType="pubmed">7966611</ArticleId></ArticleIdList></Reference><Reference><Citation>Muckelbauer, J. K., M. Kremer, I. Minor, G. Diana, F. J. Dutko, J. Groarke, D. C. Pevear, and M. G. Rossmann. 1995. The structure of coxsackievirus B3 at 3.5 &#xc5; resolution. Structure 3:653-667.</Citation><ArticleIdList><ArticleId IdType="pubmed">8591043</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy, G., S. Takatsy, E. Kukan, I. Mihaly, and I. Domok. 1982. Virological diagnosis of enterovirus type 71 infections: experiences gained during an epidemic of acute CNS diseases in Hungary in 1978. Arch. Virol. 71:217-227.</Citation><ArticleIdList><ArticleId IdType="pubmed">6285858</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolaeva, L., and A. S. Galabov. 2000. Antiviral effect of the combination of enviroxime and disoxaril on coxsackievirus B1 infection. Acta Virol. 44:73-78.</Citation><ArticleIdList><ArticleId IdType="pubmed">10989697</ArticleId></ArticleIdList></Reference><Reference><Citation>Otto, M. J., M. P. Fox, M. J. Fancher, M. F. Kuhrt, G. D. Diana, and M. A. McKinlay. 1985. In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 27:883-886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC180179</ArticleId><ArticleId IdType="pubmed">2992365</ArticleId></ArticleIdList></Reference><Reference><Citation>Pevear, D. C., T. M. Tull, M. E. Seipel, and J. M. Groarke. 1999. Activity of pleconaril against enteroviruses. Antimicrob. Agents Chemother. 43:2109-2115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC89431</ArticleId><ArticleId IdType="pubmed">10471549</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers, J. M., G. D. Diana, and M. A. McKinlay. 1999. Pleconaril: a broad spectrum antipicornaviral agent. Adv. Exp. Med. Biol. 458:69-76.</Citation><ArticleIdList><ArticleId IdType="pubmed">10549380</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero, J. R. 2001. Pleconaril: a novel antipicornaviral drug. Expert Opin. Investig. Drugs 10:369-379.</Citation><ArticleIdList><ArticleId IdType="pubmed">11178348</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann, M. G. 1989. The canyon hypothesis. Viral Immunol. 2:143-161.</Citation><ArticleIdList><ArticleId IdType="pubmed">2560913</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann, M. G. 1989. The canyon hypothesis. Hiding the host cell receptor attachment site on a viral surface from immune surveillance. J. Biol. Chem. 264:14587-14590.</Citation><ArticleIdList><ArticleId IdType="pubmed">2670920</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann, M. G., E. Arnold, J. W. Erickson, E. A. Frankenberger, J. P. Griffith, H. J. Hecht, J. E. Johnson, G. Kamer, M. Luo, A. G. Mosser, et al. 1985. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 317:145-153.</Citation><ArticleIdList><ArticleId IdType="pubmed">2993920</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossmann, M. G., and J. E. Johnson. 1989. Icosahedral RNA virus structure. Annu. Rev. Biochem. 58:533-573.</Citation><ArticleIdList><ArticleId IdType="pubmed">2673017</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotbart, H. A. 1999. Antiviral therapy for enteroviral infections. Pediatr. Infect. Dis. J. 18:632-633.</Citation><ArticleIdList><ArticleId IdType="pubmed">10440441</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawyer, M. H. 2001. Enterovirus infections: diagnosis and treatment. Curr. Opin. Pediatr. 13:65-69.</Citation><ArticleIdList><ArticleId IdType="pubmed">11176247</ArticleId></ArticleIdList></Reference><Reference><Citation>See, D. M., and J. G. Tilles. 1992. Treatment of Coxsackievirus A9 myocarditis in mice with WIN 54954. Antimicrob. Agents Chemother. 36:425-428.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC188451</ArticleId><ArticleId IdType="pubmed">1318683</ArticleId></ArticleIdList></Reference><Reference><Citation>See, D. M., and J. G. Tilles. 1993. WIN 54954 treatment of mice infected with a diabetogenic strain of group B coxsackievirus. Antimicrob. Agents Chemother. 37:1593-1598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC188025</ArticleId><ArticleId IdType="pubmed">8215268</ArticleId></ArticleIdList></Reference><Reference><Citation>Shia, K. S., W. T. Li, C. M. Chang, M. C. Hsu, J. H. Chern, M. K. Leong, S. N. Tseng, C. C. Lee, Y. C. Lee, S. J. Chen, K. C. Peng, H. Y. Tseng, Y. L. Chang, C. L. Tai, and S. R. Shih. 2002. Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. J. Med. Chem. 45:1644-1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">11931618</ArticleId></ArticleIdList></Reference><Reference><Citation>van Wezel, A. L., P. van der Marel, T. G. Hazendonk, V. Boer-Bak, and M. A. Henneke. 1983. Antigenicity and immunogenicity of poliovirus capsid proteins. Dev. Biol. Stand. 55:209-215.</Citation><ArticleIdList><ArticleId IdType="pubmed">6203795</ArticleId></ArticleIdList></Reference><Reference><Citation>Woods, M. G., G. D. Diana, M. C. Rogge, M. J. Otto, F. J. Dutko, and M. A. McKinlay. 1989. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 33:2069-2074.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC172823</ArticleId><ArticleId IdType="pubmed">2559655</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>